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A simple, sensitive, and rapid HPLC-MS/MS method was developed and validated for quantitative estimation of memantine in
human plasma. Chromatography was performed on Zorbax SB-C18 (4.6×75mm, 3.5µm) column. Memantine (ME) and internal
standard Memantine-d6(MED6) were extracted by using liquid-liquid extraction and analyzed by LC-ESI-MS/MS using multiple-
reactionmonitoring(MRM)mode.Theassayexhibitedalineardynamicrangeof50.00–50000.00pg/mlforMEinhumanplasma.
This method demonstrated an intra- and interday precision within the range of 2.1–3.7 and 1.4–7.8%, respectively. Further intra-
and interday accuracy was within the range of 95.6–99.8 and 95.7–99.1% correspondingly. The mean recovery of ME and MED6
was 86.07±6.87 and 80.31±5.70%, respectively. The described method was successfully employed in bioequivalence study of ME
in Indian male healthy human volunteers under fasting conditions.
1.Introduction
Memantine (1-amino-3,5-dimethyladamantane hydrochlo-
ride) (Figure 1) acting on the glutamatergic system by block-
ing N-methyl-D-aspartate (NMDA) glutamate receptors [1].
Memantine (ME) is used in Parkinson’s disease and move-
ment disorders, and recently it has been demonstrated to be
useful in dementia syndrome. The mode of action is thought
to be due to prevention of damage to retinal ganglion as a
result of increased intraocular pressure. The accumulation of
adruginmelanin-richtissuesmayhaveseriousphysiological
consequences as it could lead to potentially toxic eﬀects.
Despiteseveralinvestigationsintothenatureofdrugmelanin
binding, the exact mechanism of the interaction remains
unknown. ME is well absorbed, with peak plasma concen-
trations (Cmax) ranging from 22 to 46ng/mL following a
single dose of 20mg. The time to achieve maximum plasma
concentration (Tmax) following single doses of 10–40mg
ranges from 3 to 8hr. The drug is 45% bound to plasma
proteins presenting a distribution volume of approximately
9–11L/kg, which suggests an extensive distribution into
tissues. It is poorly metabolized by the liver, and 57–82%
of the administered dose is excreted unchanged in the urine
with a mean terminal half-life of 70hr [1].
There were few methods established previously to deter-
mine ME in a variety of matrices with diﬀerent instruments.
These methods include LC-MS [1–4], HPLC [5–8], GC-
MS [9], and Micellar electrokinetic chromatography [10].2 Journal of Analytical Methods in Chemistry
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Figure 1: Chemical structures of (a) Memantine hydrochloride and (b) Memantine-D6HCL.
Among all methods LC-MS [1–4] has gained more impor-
tance.
Liu et al. [1] developed the method with the linear con-
centration range of 0.2–200ng/mL, with 0.2ng/mL sensitiv-
ity. This sensitivity was improved by Almeida et al. [2]. They
developed the method with the linear concentration range
of 0.1 to 50ng/mL, with 0.1ng/mL sensitivity. Pan et al. [3]
developed the method with the linear concentration range
of 0.1 to 25ng/mL. They used 0.5mL plasma usage to get
0.1ng/mL of sensitivity. Koeberle et al. [4] developed the
method in diﬀerent melanins.
The reported methods do not show the usage of deuter-
ated internal standard comparision with analyte which is
most important in bioanalytical method development. All
the reported methods develop the method with long run
time and more amount of plasma sample for extraction.
The purpose of this investigation was to develop a rapid,
simple, sensitive, and selective LC-MS/MS method for the
quantitative estimation of ME in less volume of human
plasma using deuterated internal standard. It is also expect-
ed that this method would provide an eﬃcient solution
for pharmacokinetic, bioavailability, and/or bioequivalence
studies of ME.
2.MaterialsandMethods
2.1. Chemicals. ME (99.9%) was obtained from Varda
biotech Pvt. Ltd. Andheri, Mumbai, India. MED6 (99.0%)
wasobtainedfromtheTorontoResearchChemicals,Toronto,
Canada. Blank plasma lots were purchased from Navjeevan
blood bank, Hyderabad. HPLC-grade methanol and ace-
tonitrile were purchased from Jt. Baker, USA. Diethyl ether
and n-hexane were purchased from Lab Scan, Asia Co. Ltd,
Bangkok, Thailand. Formic acid and sodium hydroxide were
purchased from Merck Mumbai, India. HPLC-grade water
from Milli-Q System was used. All other chemicals used were
analytical grade.
2.2. Instrumentation and Chromatographic Conditions.
HPLC system (1200 series, Agilent Technologies, Germany)
is connected with API 4000 triple quadrupole mass spec-
trometer (ABI-SCIEX, Toronto, Canada) using multiple re-
action monitoring (MRM). A turbo electrospray interface
in positive ionization mode was used. Data processing was
performed on Analyst 1.4.1 software package (SCIEX).
The chromatography was performed on a Zorbax SB-C18
(4.6 × 75mm, 3.5µm) (Agilent technologies,Germany) at
40◦C temperature. The mobile phase composition was a
mixture of 0.1% formic acid:acetonitrile (35:65v/v) which
was pumped at a ﬂow-rate of 0.6mL/min without split.
2.3. Preparation of Calibration Standards and Quality Control
Samples. Standard stock solutions of ME (100.00µg/mL)
and MED6 (100.00µg/mL) were separately prepared in
methanol. MED6 dilution (25.00ng/mL) was made from
MED6standardstocksolutionwithdiluent(methanol:water
50:50v/v). Standard stock solution of ME was added to
drug-free human plasma to obtain ME calibration stan-
dards of 50.00, 100.00, 500.00, 1000.00, 5000.00, 10000.00,
20000.00, 30000.00, 40000.00, and 50000.00pg/mL. Quality
control (QC) samples were also prepared as a bulk on an
independent weighing of standard drug at concentrations
of 50.00 (LLOQ), 150.00 (LQC), 15000.00 (MQC), and
35000.00pg/mL (HQC) from standard stock solutions of
ME. The calibration standards and quality control samples
were divided into aliquots in 5mL Ria vials and stored in the
freezer at below −30◦C until analysis.
2.4. Sample Preparation. 50µL of MED6 (25ng/mL), 100µL
of plasma sample, and 100µLo f1 0m MN a O Hw e r ea d d e d
into 5mL Ria vials and vortexed brieﬂy. This was followed by
addition of 3mL extraction solvent (diethyl ether:n-hexane
70:30v/v) and vortexed for 10min. Then samples were
centrifuged at 4000rpm for 5min at ambient temperature
conditions. Then, the supernatant from each sample was
transferred into labelled vials by using the dry-ice acetone
ﬂash freeze technique and evaporated to dryness under
n i t r o g e ns t r e a ma t4 0 ◦C .T h ed ri e dr e s i d u ew a sr e c o n s t i t u t e d
with 400µL of 0.1% of formic acid: acetonitrile (35:65 v/v)
mixture and vortexed until dissolved. Finally, a 20µLo fe a c h
sample was transferred into auto sampler vials and injected
into HPLC connected with mass spectrometer.
2.5. Recovery. Recovery of ME was evaluated by comparing
the mean peak area of six extracted low, medium, and
high (150.00, 1500.00, and 35000.00pg/mL) quality control
samples to the mean peak area of six aqueous standardsJournal of Analytical Methods in Chemistry 3
with the same concentrations of low, medium, and high ME
quality control samples.
Similarly the recovery of MED6 was evaluated by com-
paring the mean peak area of extracted quality control sam-
ples to the mean peak area of MED6 in aqueous standards
samples with the same concentrations of MED6.
2.6.Selectivity. Theselectivityofthemethodwasdetermined
by blank human plasma samples from six diﬀerent healthy
human volunteers to test the potential interferences of endo-
genouscompoundscoelutedwithMEandMED6.TheChro-
matographic peaks of ME and MED6 were identiﬁed on the
basis of their retention times and MRM responses. The mean
peak area of LOQ for ME and MED6 at corresponding reten-
tion time in blank samples should not be more than 20 and
5%, respectively.
2.7. Limit of Quantiﬁcation (LOQ). The LOQ was estimated
in accordance with the baseline noise method at a signal-to-
noise ratio (S/N) of 5. It was experimentally determined by
injecting six samples with ME at the LLOQ concentration.
The acceptance criterion for S/N was ≥5a n dc a l c u l a t e db y
selecting the noise region as close as possible to the signal
peak, which was at least 8 times of the signal peak width at
half height.
2.8. Analytical Curves. The analytical curves of ME were
constructed in the concentrations ranging from 50.00 to
50000.00pg/mL in human plasma. The calibration curve
was constructed by using instrument response (ratio of ME
peak area to MED6 peak area) against the ME concentra-
tion (pg/mL) for four consecutive days by weighted 1/x2
quadratic regression model. The ﬁtness of calibration curve
was conﬁrmed by back-calculating the concentrations of
calibration standards.
2.9. Calibration Curve Standards, Regression Model, Precision,
and Accuracy Batches. Calibration curve standard samples
and QC samples were prepared in replicates (n = 6)
for analysis. Correlation coeﬃcients (r2) were obtained by
using quadratic regression model in whole range of tested
concentrations. The accuracy and precision for the back
calculated concentrations of the calibration points should
be within ±15% whereas those of LLOQ should be within
±20% of their nominal values.
2.10. Stability. Low and high QC samples (n = 6) were
retrieved from the deep freezer; samples were processed for
three freeze/thaw cycles according to the clinical protocols.
The samples were stored at −10◦Ct o−30◦C in three cycles
of24,36,and48hr.Inaddition,thelong-termstabilityofME
in QC samples was also evaluated after 76 days of storage at
−10 to −30◦C. The stability at refrigerated temperature was
studied following 79hr storage period in the autosampler
tray. Bench top stability was studied for 26-hour period.
Stability samples were processed and extracted along with
the freshly spiked calibration curve standards. Stability of the
stock solutions was proved for 24 days. The precision and
accuracy for the stability samples were maintained within 15
and ±15%, respectively, of their nominal concentrations.
2.11. Matrix Eﬀect. The matrix eﬀect due to plasma matrix
was used to evaluate ion suppression/enhancement in a
signal by comparing the absolute response of QC samples
after pretreatment (liquid-liquid extraction) with that of
reconstituted samples extracted blank plasma sample spiked
with analyte. Experiments were performed at low and high
concentration levels in triplicate. The acceptable precision
(%CV) should be ≤15%.
2.12. Analysis of Human Plasma Samples. The bioanalytical
method described previously was applied to determine ME
concentrations in plasma following oral administration to
healthy adult human male volunteers below 25 years of
age. The volunteers were contracted by Micro Therapeutics
Research Labs Pvt Ltd., Chennai, India. They were screened
before participation in the study and an informed consent
was taken from them. These volunteers, were not undergone
any other medication before conducting this study. To each
of the 20 volunteers a tablet containing 10mg of ME was
orally administered along with a 240mL of drinking water.
Proper diet was provided to each volunteer as per the
protocol. The reference product (Namenda tablets 10mg,
Forest laboratories, Ireland) and test product (Memantine
tablets 10mg) were used in the study. The study protocol was
approved by IEC (Institutional Ethical Committee) and by
ICMR (Indian Council of Medical Research). Blood samples
were collected as predose (0hr) 5 minutes prior to dosing
followed by further samples at 1, 2, 3, 4, 4.5, 5, 5.5, 6, 6.5,
7, 7.5, 8, 12, 24, 48, and 72hr. After dosing, a 5mL blood
sample was collected each preestablished time in vacutainers
containing K2EDTA. A total of 34 samples (17 time points
each for reference and test) were collected and centrifuged
at 3200rpm and10◦C for 10min. Then they were stored
at −30◦C until further analysis. Test and reference were
administered to the same human volunteers under fasting
conditions separately after a washing period of 18 days as per
protocol approved by IEC.
2.13. Pharmacokinetics and Statistical Analysis. Pharmacoki-
netics parameters were calculated from plasma levels apply-
ing a noncompartmental statistics model using WinNon-Lin
5.0 software (Pharsight, USA). Following Food and Drug
Administration (F.D.A) guideline [11, 12], blood samples
were drawn up to a period of three to ﬁve times the terminal
elimination half-life (t1/2) and it was considered as the area
under the concentration time curve (AUC) ratio higher than
80%. The Cmax and Tmax values were determined by visual
inspection of the plasma ME concentration-time proﬁles.
The area under the concentration-time curve (AUC0−t)w a s
obtained by the trapezoidal method. The total area under the
curve (AUC0−∞) was calculated up to the last measureable
concentration, and extrapolations were obtained by the last
measureable concentration and the terminal elimination
rate constant (Ke). The Ke was estimated from the slope
of the terminal exponential phase of the plasma of ME4 Journal of Analytical Methods in Chemistry
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Figure 2:(a)MassspectraofMemantineparention(Q1).(b)MassspectraofMemantineproduction(Q3).(c)MassspectraofMemantine-
D6 parent ion. (d) Mass spectra of Memantine-D6 product ion (Q3).
concentration-time curve using linear regression method.
The t1/2 was then calculated as 0.693/Ke. The AUC0−t,
AUC0−∞,a n dCmax bioequivalence were assessed by analysis
of variance (ANOVA), and the standard 90% conﬁdence
intervals (90% CIs) of the ratios test/reference were cal-
culated after transforming the data logarithmically. The
bioequivalence was considered when the ratio of averages
of log transformed data was within 80–125% for AUC0−t,
AUC0−∞,a n dCmax [11, 12].
3. Results and Discussion
3.1.MethodDevelopmentandValidation. Massspectrometry
parameters, fragmentation pattern, and mode of ionization
are the main task in mass spectrometry tuning to obtain
respective fragmented ions and response for both ME
and MED6 which were shown in Figures 2(a), 2(b), 2(c),
and 2(d). ESI-LC-MS/MS is a very powerful technique
for pharmacokinetic studies since it provides sensitivityJournal of Analytical Methods in Chemistry 5
and selectivity requirements for analytical methods. MRM
technique was chosen for the assay development. The MRM
parameters were optimized to maximize the response for the
analyte.
The instrumental parameters for mass spectroscopy were
optimized. The source temperature was 600◦C. The gas pres-
sures of nebulizer, heater, curtain, and CAD were 40, 30, 20,
and4psi,respectively.Theionsprayvoltage,entrancepoten-
tial, declustering potential, collision energy, and collision cell
exit potential were optimized at 5500, 10, 50, 32, and 12V,
respectively. The dwell time was 400 milliseconds for both
ME and MED6.
The product ion (Q3) mass spectra of ME and the
MED6 are shown in Figures 2(b) and 2(d).[ M+H ] + was
the predominant ion in the Q1 spectrum. The Q1 for ME
and MED6 was 180.2 and 186.1, respectively, and were used
as the precursor ion to obtain product ion spectra. The
collisionally associated dissociation (CAD) mass spectrum
of ME shows formation of characteristic product ions at
m/z 161.8, 163.2, and 165.1. The major product ion at
m/z 163.2 for ME could be explained by the splitting of
1-amino-3-,5-dimethyladamantane hydrochloride from the
protonated precursor molecule. The CAD mass spectrum of
MED6 shows formation of characteristic product ions at m/z
169.2. The major product ion at m/z 169.2 arose from 3,5-
Dimethyl-d6-tricyclo-[3,3,1,13,7]decan-1-amine,3,5-Dim-
ethyl-d6-1-adamantanamine from the protonated precursor
molecule. The most sensitive mass transitions were from m/z
180.2 to 1163.2 for ME and m/z 186.1 to m/z 169.2 for the
MED6.TheproposedfragmentationpatternisFigure 2(a)→
Figure 2(b), Figure 2(c)→Figure 2(d). The inherent selecti-
vity of MS-MS detection was also expected to be beneﬁcial
in developing a selective and sensitive method.
The chromatographic conditions particularly the com-
position of mobile phase, ﬂow-rate of mobile phase, choos-
ing of suitable column, injection volume, column oven tem-
perature, autosampler temperature, splitting of sample in to
ion source, as well as a short run time were optimized
through several trials to achieve good resolution and sym-
metric peak shapes for the ME and MED6. It was found
that a mixture of 0.1% formic acid:acetonitrile (35:65v/v)
could achieve this purpose and this was ﬁnally adopted as
the mobile phase. The formic acid was found to be necessary
in order to lower the pH to protonate the ME and thus
deliver good peak shape. The percentage of formic acid was
optimized to maintain this peak shape while being con-
sistent with good ionization and fragmentation in the mass
spectrometer. The high proportion of organic solvent eluted
both the ME and the MED6 at retention time 1.45 ±0.2min
ataﬂowrateof0.6mL/min,producedgoodpeakshapes,and
permitted a run time of 3.5min.
Liquid-liquid extraction (LLE) was used for the sample
preparation in this work. LLE can be helpful to clean the
samples. Clean samples are essential for minimizing ion
suppressionandmatrixeﬀectinLC-MS/MSanalyses.Several
organicsolventsandtheirmixturesindiﬀerentcombinations
and ratios were evaluated. Finally, diethyl ether/n-hexane
(70:30) was found to be optimal, which produced a clean
chromatogram for a blank plasma sample and yielded the
Table 1: Concentration data form validation.
Spiked plasma
concentration
(pg/ml)
Concentration
measured (pg/ml)
Mean ± Sd
n = 5
Precision
(% CV)
Accuracy
%
50.00 49.92 ±0.44 0.80 99.23
100.00 100.21 ±1.91 1.90 98.14
500.00 502.73 ±6.83 1.40 98.65
1000.00 1000.54 ±11.53 1.10 98.92
5000.00 5005.06 ±38.75 0.80 99.28
10000.00 9978.95 ±160.56 1.60 98.45
20000.00 19871.04 ±303.46 1.50 98.53
30000.00 29759.82 ±508.47 1.70 98.37
40000.00 40310.88 ±123.85 0.30 99.74
50000.00 50084.85 ±266.72 0.50 99.55
highest recovery for the ME and MED6 from the plasma.
Memantine-D6 hydrochloride was used as internal stan-
dard for the present purpose. Clean chromatograms were
obtained, and no signiﬁcant direct interferences in the MRM
channels at the relevant retention times were observed.
3.2. Selectivity. The selectivity of the method was examined
by analyzing blank human plasma extracts (n = 6). The
result of one blank (Figure 3(a)) plasma is shown and the
lack of interference is similar to other samples which were
studied which shows no signiﬁcant direct interference in the
blankplasmatracesasobservedfromendogenoussubstances
in drug-free human plasma at the retention time of the
analyte.
3.3.LimitofQuantiﬁcation(LOQ). TheLOQsignal-to-noise
(S/N) value found for 6 injections of ME at LOQ concen-
tration was 11.93. Figure 3(b) shows a representative ion-
chromatogram for the LOQ (50pg/mL) with 20µL injection
volume.
3.4. Linearity, Precision, and Accuracy. The ten-point calibra-
tion curve was linear over the concentration range 50.00–
50000.00pg/mL. The calibration model was selected based
on the analysis of the data by quadratic regression with
intercepts and weighting factor 1/x2. The best quadratic
regression for the calibration curve was achieved with a
1/x2 weighing factor, giving a mean quadratic regression
equation for the calibration curve of y =− 9.427×10
−11x2 +
9.194 × 10
−5x +2 .989 × 10
−4(y = ax2 + bx + c)w h e r e
y is the peak-area ratio of the ME to the MED6 and x
is the concentration of the ME in plasma (Table 1). For
the between-batch experiments, the precision and accuracy
ranged from 1.4 to 2.7% and 95.7 to 99.1%, respectively
(Table 2). Further, in within-batch experiments the precision
and accuracy ranged from 2.1 to 2.3% and 95.6 to 99.8%
correspondingly.6 Journal of Analytical Methods in Chemistry
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Figure 3: (a) MRM chromatogram for blank plasma. (b) Chromatogram of LOQ.
Table 2: Precision and accuracy (analysis with spiked plasma samples at three diﬀerent concentrations).
Spiked plasma
concentration
(pg/ml)
Within-run (n = 6) Between-run (n = 30)
Concentration
measured (n = 6)
(pg/ml) (mean ± Sd.)
Precision (%CV) Accuracy %
Concentration
measured (n = 30)
(pg/ml) (mean ± Sd.)
Precision (%CV) Accuracy %
150.00 143.40 ±3.20 2.20 95.60 143.50 ±3.90 2.70 95.70
15000.00 14746.40 ±338.40 2.30 98.30 14719.10 ±248.30 1.70 98.10
35000.00 34935.20 ±730.40 2.10 99.80 34699.20 ±498.40 1.40 99.10Journal of Analytical Methods in Chemistry 7
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Figure 4: Mean plasma concentrations of test versus reference after
a 10mg dose (one 10mg tablet) single oral dose (20 healthy volun-
teers).
Table 3: Stability of Memantine in human plasma samples.
Spiked plasma
concentration
(pg/ml n = 6)
Concentration
measured
(pg/ml)
Precision
(%CV) Accuracy (%)
Room temperature stability for 26hr in plasma
150.00 151.23 1.00 100.82
35000.00 34926.50 0.80 99.79
Three freeze-thaw cycles
150.00 153.02 2.30 102.01
35000.00 34818.00 0.90 99.48
Auto sampler stability for 79hr
150.00 154.59 1.40 103.06
35000.00 35213.50 0.90 100.61
Stability for 76 days −30◦C
150.00 151.53 3.20 101.02
35000.00 35080.50 1.40 100.23
3.5. Recovery. The recoveries for ME at low (150.00pg/mL),
medium (15000.00pg/mL) and high (35000.00pg/mL) plas-
ma concentrations with six replicate injections each showed
79.45±6.20%, 91.25±5.9%, and 87.52±2.59%. The overall
recovery of ME was found to be 86.07% ± 6.87%. Similarly
extraction recovery of MED6 (25.00ng/mL) was determined
as 80.31% ± 5.70%. Recoveries of ME and MED6 were high,
precise, and reproducible. Therefore, the assay has proved to
be robust in high-throughput bioanalysis.
3.6. Stability Studies. Quantiﬁcation of the ME in plasma
that was subjected to 3 freeze-thaw cycles (−30◦Ct or o o m
temperature) showed the stability of the analyte. The con-
centrationsrangedfrom98.00to104.00%forME.Nosignif-
icant degradation was observed even after a 79-hour storage
Table 4: Mean pharmacokinetic parameters of Memantine in 20
healthy human volunteers after oral administration of 10mg test
and reference products.
Pharmacokinetic details of Memantine in human plasma
Pharmacokinetic
Parameter
Reference Test
Mean ± SD Mean ± SD
Cmax (pg/ml) 14368.57 ±4044.16 14328 ±4324.76
AUC0−t (pg·hr/ml) 654545.5 ±70423.12 674564.4 ±67858.99
AUC0−∞ (pg·hr/ml) 1053469.0±77690.79 1136607 ± 74862.04
Tmax (hr) 7.0 7.5
t1/2 49.29 53.35
AUC0−∞: Area under the curve extrapolated to inﬁnity.
AUC0−t: Area under the curve up to the last sampling time.
Cmax: The maximum plasma concentration.
Tmax:T h et i m et or e a c hp e a kc o n c e n t r a t i o n .
Table 5: Pharmacokinetic parameters of memantine after adminis-
tration of 10mg of test and reference products in 20 healthy human
volunteers.
Pharmacokinetic
parameters Cmax (T/R) AUC0−t (T/R) AUC0−∞ (T/R)
Test/Ref 99.72 103.06 107.89
period in the autosampler tray, and the ﬁnal concentrations
of ME were found between 100.00 and 105.00% The room
temperature stability of ME in QC samples after 26hr was
also evaluated. The concentrations were ranged between
99.00 and 102.00% for ME. In addition, the long-term
stability in low and high QC samples after 76 days of storage
at −30◦C was also evaluated, and the concentrations ranged
from 98.00 to 103.00% for ME. These results conﬁrmed the
stability of ME in human plasma for at least 76 days at
−30◦C. (Table 3).
3.7. Application to Biological Samples. The proposed method
was applied to the determination of ME in plasma samples
for the purpose of establishing the bioequivalence of a
single dose (10mg tablet) in 20 healthy human volunteers.
Typical plasma concentrations versus time proﬁles were
shown in Figure 4. Plasma concentrations of ME were in the
standardcurverangeandretainedaboveLLOQfortheentire
sampling period. The pharmacokinetic parameters for test
and reference products were shown in Tables 4 and 5.T h e
mean ratio of AUC0−t/AUC0−∞ was higher than 90% which
followed the Food and Drug Administration Bioequivalence
Guideline [11, 12]. The ratio of test/reference (T/R) and 90%
conﬁdence intervals (90 CIs) for overall analysis were com-
prised within the previously stipulated range (80–125%).
Therefore, it can be concluded that the two ME formulations
(reference and test) analyzed are bioequivalent in terms of
rate and extent of absorption at fasting conditions.8 Journal of Analytical Methods in Chemistry
4. Conclusion
A simple, high sensitive, speciﬁc, rugged, and reproducible
LC-MS/MS method for the determination of memantine in
human plasma was developed and validated as per FDA
guidelines. This method was successfully applied in bioe-
quivalence study to evaluate the plasma concentrations of
ME in healthy human volunteers.
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